gross profit bridgeinconsistent2016-12-31
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$11.04B
Fiscal year ended 2025-12-31Operating income
$1.56B
Fiscal year ended 2025-12-31Free cash flow
$1.36B
Fiscal year ended 2025-12-31QUEST DIAGNOSTICS INC (DGX) reported revenue of $11.04B and net income of $992.00M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from QUEST DIAGNOSTICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B |
| Cost of revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | Unavailable |
| Gross profit | $3.66B | $3.24B | $3.05B | $3.43B | $4.21B | $3.63B | $2.69B | $2.60B | $2.68B | Unavailable |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.16B | $1.28B |
| Net income | $992.00M | $871.00M | $854.00M | $946.00M | $2.00B | $1.43B | $858.00M | $736.00M | $772.00M | $645.00M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 113.00M | shares 113.00M | shares 113.00M | shares 118.00M | shares 128.00M | shares 136.00M | shares 136.00M | shares 139.00M | shares 140.00M | shares 142.00M |
| Pretax income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926.00M | $1.03B | $1.09B |
| Income tax expense | $314.00M | $273.00M | $248.00M | $264.00M | $597.00M | $460.00M | $247.00M | $182.00M | $241.00M | $429.00M |
| Diluted EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 |
| Selling, general & administrative | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $420.00M | $549.00M | $686.00M | $315.00M | $872.00M | $1.16B | $1.19B | $135.00M | $137.00M | $359.00M |
| Total assets | $16.22B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B |
| Current assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $2.28B | $2.17B | $1.82B | $1.55B | $1.75B | $1.78B | $1.99B | $1.48B | $1.06B | $981.00M |
| Total equity incl. NCI | $7.21B | $6.81B | $6.34B | $5.93B | $6.48B | $6.81B | $5.69B | $5.27B | $4.96B | $4.66B |
| Temporary (mezzanine) equity | $80.00M | $83.00M | $76.00M | $77.00M | $79.00M | $82.00M | $76.00M | $77.00M | $80.00M | $77.00M |
| Inventory | $189.00M | $188.00M | $190.00M | $192.00M | $208.00M | $223.00M | $123.00M | $99.00M | $95.00M | $82.00M |
| Accounts receivable | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924.00M | $926.00M |
| Goodwill | $8.94B | $8.86B | $7.73B | $7.22B | $7.10B | $6.87B | $6.62B | $6.56B | $6.34B | $6.00B |
| Long-term debt | $5.17B | $5.62B | $4.41B | $3.98B | $4.01B | $4.01B | $3.97B | $3.43B | $3.75B | $3.73B |
| Accounts payable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B |
| Capital expenditures | $527.00M | $425.00M | $408.00M | $404.00M | $403.00M | $418.00M | $400.00M | $383.00M | $252.00M | $293.00M |
| Investing cash flow | -$631.00M | -$2.55B | -$1.06B | -$543.00M | $21.00M | -$772.00M | -$411.00M | -$801.00M | -$830.00M | -$127.00M |
| Financing cash flow | -$1.39B | $1.08B | $160.00M | -$1.73B | -$2.54B | -$1.27B | $225.00M | -$401.00M | -$592.00M | -$738.00M |
| Net change in cash | -$129.00M | -$137.00M | $371.00M | -$557.00M | -$286.00M | Unavailable | Unavailable | Unavailable | -$222.00M | $226.00M |
| Stock-based compensation | $88.00M | $88.00M | $77.00M | $77.00M | $79.00M | $97.00M | $56.00M | $61.00M | $79.00M | $69.00M |
| Common dividends paid | $353.00M | $331.00M | $314.00M | $305.00M | $309.00M | $297.00M | $286.00M | $266.00M | $247.00M | $223.00M |
| Common share repurchases | $450.00M | $151.00M | $275.00M | $1.41B | $2.20B | $325.00M | $353.00M | $322.00M | $465.00M | $590.00M |
| Depreciation & amortization | $570.00M | $493.00M | $439.00M | $437.00M | $408.00M | $361.00M | $329.00M | $309.00M | $270.00M | $249.00M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.36B | $909.00M | $864.00M | $1.31B | $1.83B | $1.59B | $843.00M | $817.00M | $923.00M | $823.00M |
| Gross margin | 33.2% | 32.9% | 33.0% | 34.7% | 39.0% | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Operating margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.7% | 17.7% |
| FCF margin | 12.3% | 9.2% | 9.3% | 13.3% | 17.0% | 16.8% | 10.9% | 10.8% | 12.5% | 11.4% |
| SBC / revenue | 0.8% | 0.9% | 0.8% | 0.8% | 0.7% | 1.0% | 0.7% | 0.8% | 1.1% | 1.0% |
| Current ratio | 1.04x | 1.10x | 1.31x | 1.22x | 1.56x | 1.72x | 1.25x | 0.94x | 1.24x | 1.56x |
| Revenue YoY growth | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | 22.1% | 2.6% | 1.7% | 2.6% | Unavailable |
| Net margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.4% | 8.9% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 4.8% | 4.3% | 4.4% | 4.1% | 3.7% | 4.4% | 5.2% | 5.1% | 3.4% | 4.1% |
| Long-term debt / equity | 0.72x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 23.8% | 23.2% | 21.9% | 21.4% | 23.0% | 24.4% | 23.0% | 19.7% | 23.4% | 39.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DGX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-22View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-21View SEC filing
10-Q · Filed 2025-07-23View SEC filing
10-Q · Filed 2025-04-23View SEC filing
Reconciliation checks needing review
3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
cash flow reconciliationreview2017-12-31
Operating, investing and financing flows differ from the reported change in cash by 25000000, beyond tolerance 11750000.00.
cash flow reconciliationreview2016-12-31
Operating, investing and financing flows differ from the reported change in cash by 25000000, beyond tolerance 11160000.00.